Vincerx Pharma climbs on positive data from early-stage cancer therapy trial

Vincerx Pharma

08/01/2024 12:56

** Shares of drug developer Vincerx Pharma  VINC.O  soars
52.5% to $1.8 premarket  
    ** Co announced positive results from its early-stage study
testing its experimental combination cancer therapy in patients
with a type of blood cancer  
    ** The experimental drug, enitociclib, in combination with
two other cancer drugs showed high response rate and
tolerability  
    ** The combination therapy helped in shrinking the tumor by
at least 50% in four patents in early-stage study 
    ** Stock rose 15.7% in 2023 
    

 (Reporting by Sneha  S K)
 ((Sneha.SK@thomsonreuters.com;))